News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Noninvasive UGN-102 therapy delivers durable response in recurrent LG-IR-NMIBC
05 Aug 2026
byStephen Padilla
Patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) who achieved an initial complete response (CR) to UGN-102 treatment tend to remain event-free 24 months later, according to phase III ENVISION trial.








